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Herpesvirus carriers transmit infection despite making virus-specific antibodies. Thus, their antibody responses are not
necessarily optimal. An important question for infection control is whether vaccinating carriers might improve virus
neutralization. The antibody response to murine gamma-herpesvirus-68 (MHV-68) blocks cell binding, but fails to block and
even enhances an IgG Fc receptor-dependent infection of myeloid cells. Viral membrane fusion therefore remains intact.
Although gH/gL-specific monoclonal antibodies can block infection at a post-binding step close to membrane fusion, gH/gL is
a relatively minor antibody target in virus carriers. We show here that gH/gL-specific antibodies can block both Fc receptor-
independent and Fc receptor-dependent infections, and that vaccinating virus carriers with a gH/gL fusion protein improves
their capacity for virus neutralization both in vitro and in vivo. This approach has the potential to reduce herpesvirus
transmission.
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INTRODUCTION
Persistent viruses have evolved to co-exist with established host
immunity. Herpesviruses are among the most successful, and
provide an archetype for many of the immune evasion
mechanisms that underlie effective persistence [1–3]. In contrast
to the plethora of information about T cell evasion, relatively little
is known about how herpesviruses evade neutralization by
antibody. They must do so, since they continue to transmit
infection despite eliciting virus-specific antibodies; by contrast, pre-
existing antibodies generally block the transmission of non-
persistent viruses. Epidemiological evidence would suggest that
herpesvirus antibody evasion is efficient enough even to avoid
much selection of viral antigenic variants [4].
It is important when considering antibody evasion to distinguish
Fab-dependent neutralization from Fc-dependent antibody func-
tions such as cytotoxicity and opsonization. Herpesviruses transmit
between hosts as cell-free virions. Here, antibody evasion must be
an evasion of neutralization. In contrast, herpesviruses mainly
spread within their hosts via cell/cell contacts [5,6]. These limit
virion exposure to antibody [7], so antibody-dependent cytotox-
icity is probably a more important host defence than neutralization
[8,9]. Other Fc receptor (FcR)-dependent effector mechanisms
may also operate [10,11]. Alpha-herpesviruses encode FcR
homologs [12] that inhibit host FcR-dependent functions [13].
This reflects that their latency in terminally differentiated neurons
makes host colonization highly dependent on lytic spread. In
contrast, gamma-herpesviruses colonize their hosts mainly by
latency-associated lymphoproliferation [14–16]. This may explain
why they do not encode FcRs. Yet gamma-herpesvirus must still
evade neutralization. A blockade of cell binding by immune serum
neutralizes murine gamma-herpesvirus-68 (MHV-68) for infection
of FcR
2 cells, but not FcR
+ cells [17]. Thus, opsonization can
rescue the infectivity of antibody-coated virions. This implies that
virion membrane fusion still operates, since it is an essential step in
infection by any route. FcR-dependent infection is also described
for beta-herpesviruses [18,19]. Although MHV-68 productively
infects FcR
+ cells, latency usually pre-dominates and virus
production is therefore more protracted than in epithelial cells
[17,20]. Thus, with opsonization the likely effects of antibody on
transmission and cell/cell spread diverge. By diverting virions into
myeloid cells, antibody should damp down MHV-68 lytic infection
even when it fails to achieve neutralization. It is the need for
transmission rather than the capacity to cause disease that drives
viral evolution. A disease readout is therefore not the best way to
understand gamma-herpesvirus antibody evasion.
The MHV-68 glycoprotein-specific antibody response pre-
dominantly targets gp150, and gp150-specific antibodies account
for most of the FcR-dependent infection that is driven by immune
sera [21]. Monoclonal antibodies (mAbs) directed against gH/gL
block infection at a post-binding step close to membrane fusion
[22]. However, gH/gL appears to be poorly immunogenic, as gH/
gL-specific antibodies are only a minor component of the total
response [21]. Viral membrane fusion remains obligatory
whatever the route of infection. So if gH/gL-specific antibodies
can also block FcR-dependent infection, a weak gH/gL-specific
response might be crucial to viral evasion of neutralization, and
inducing stronger gH/gL-specific immunity might be a means of
reducing viral spread. The steady state CD8
+ T cell response of
MHV-68 carrier mice is not fixed, but can be altered by post-
exposure vaccination [23]. Such an approach also has the
potential to alter antibody responses. We have tested here whether
the presentation of gH/gL alone, without its usual accompaniment
of more immunogenic MHV-68 virion glycoproteins, can shift the
antibody response of virus carriers towards better neutralization.
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gH/gL-specific antibodies inhibit FcR-dependent
MHV-68 infection
We first sought to establish whether gH/gL-specific mAbs could
block FcR-dependent infection (Fig. 1). We have shown previously
[17] that RAW264.7 macrophages provide a reasonable model of
the interaction between antibody-coated virions and FcR
+ cells,
and have validated eGFP expression from the MHV-68 genome as
a comparative measure of infection between cell populations [17].
We therefore used this system for in vitro analysis. In contrast to the
non-neutralizing gp70-specific mAb 6H10, the neutralizing gH/
gL-specific mAb 7D6 failed to enhance the infection of RAW264.7
macrophages by wild-type MHV-68 and inhibited their infection
by gp150-deficient MHV-68 (Fig. 1A). (Gp150-deficient MHV-68
shows enhanced infection of cells such as macrophages that have
low glycosaminoglycan expression [24,25].) MAb 7D6 also
blocked BHK-21 cell infection by both viruses. Baseline
RAW264.7 cell infection by wild-type MHV-68 was too low to
identify clear reductions by fluorescence microscopy, but an
inhibition of infection by various gH/gL-specific mAbs was
evident on flow cytometry (Fig. 1B). A gH/gL-specific mAb was
also able to reverse the FcR-dependent infection driven by a non-
neutralizing gp150-specific mAb (Fig. 1C).
The gH/gL-specific component of immune serum
limits FcR-dependent MHV-68 infection
Although immune sera mainly promote FcR-dependent MHV-68
infection [17], very high doses of some sera can be inhibitory. To
test what gH/gL-specific antibodies normally contribute to the
effect of whole serum on FcR-dependent infection, we compared
sera from mice infected with wild-type or gL-deficient [26] MHV-
68 (Fig. 2). gL-deficient MHV-68 mutants colonize mice much like
the wild-type [26], and are just equally immunogenic as measured
by ELISA for total MHV-68-specific serum antibody (data not
shown). However, they elicit no gH/gL-specific antibodies,
because they express no gL-dependent epitopes [26].
Wild-type immune serum neutralized both wild-type and gL-
knockout virions for BHK-21 cell infection. gL knockout-immune
serum neutralized wild-type MHV-68 relatively poorly, consistent
with gH/gL being a major neutralization target [22]. But much
more striking was its very strong enhancement of FcR-dependent
infection by wild-type virions. In contrast, gL knockout-immune
serum inhibited FcR-dependent infection by gL-knockout virions.
This may reflect that gH alone is more readily neutralized than
gH/gL. Note that gH-specific antibodies are also present in wild-
type immune sera [26]. Thus, it appeared that both monoclonal
Figure 1. Global inhibition of MHV-68 infection by gH/gL-specific
mAbs. A. Wild-type or gp150-deficient (gp150
2) eGFP-expressing MHV-
68 virions were incubated (1 mg mAb/10
4 p.f.u.) with mAb 6H10 (anti-
gp70, IgG2a, non-neutralizing) or mAb 7D6 (anti-gH/gL, IgG2a,
neutralizing), or with no antibody (virus only), then added to
RAW264.7 macrophages (1 p.f.u./cell) or BHK-21 fibroblasts (0.1 p.f.u./
cell). 18 h later, infected cells were identified by viral eGFP expression,
and appear dark in this image. The data are from 1 of 5 equivalent
r
experiments. B. Wild-type eGFP-expressing MHV-68 virions (10
5 p.f.u.)
were incubated (2 h, 37uC) with 1 of 4 different gH/gL-specific mAbs or
without antibody (virus only). The virus/antibody mixtures were then
added to RAW264.7 cells (1 p.f.u./cell). 18 h later, infected cells were
enumerated by flow cytometry of viral eGFP expression. The dashed
line shows the level of infection with virus alone. The data are from 1 of
3 equivalent experiments. C. EGFP-expressing MHV-68 was incubated
(2 h, 37uC) with mAb T1A1 (20 mg/ml) or not, plus either the
neutralizing, gH/gL-specific mAb 7E5 or the anti-H2-K
b mAb Y3 as
a negative control. The virus/antibody mixtures were then used to
infect BHK-21 fibroblasts (1 p.f.u./cell) or RAW264.7 macrophages (5
p.f.u./cell). Infection was quantitated 18 h later by flow cytometry of
viral eGFP expression. UI=uninfected, VIR=virus only. The data are
from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000899.g001
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pendent MHV-68 infection. This argued that the level of gH/gL-
specific immunity critically determines the fate of antibody-
exposed virions.
Boosting gH/gL-specific immunity reduces IgG FcR-
dependent and FcR-independent infections
We next tested whether neutralizing antibodies can be boosted by
post-exposure vaccination of MHV-68 carrier mice. Our first task
was to express a suitable form of gH. Although gH alone can reach
the cell surface, it does so in a conformation not recognized by
neutralizing mAbs [22]. To ensure that gH would adopt a suitable
conformation, we fused it to gL. Since a glycosyl-phosphatidyl-
inositol (GPI)-linked form of gL can fold gH in transfected cells
[22], gL is probably sited close to the membrane in the mature
gH/gL heterodimer. We therefore fused gL to the C-terminus of
the gH extracellular domain (gHL), again with a GPI anchor. Cells
transfected with this fusion protein were recognized by all our gH/
gL-specific neutralizing mAbs (n.30, data not shown). For gene
delivery, we transferred this construct into vaccinia virus. Cells
infected with vaccinia virus expressing the gHL fusion protein
(VAC-gHL) displayed gH/gL neutralization epitopes (Fig. 3A).
We also generated a vaccinia virus recombinant (VAC-gB)
expressing the gB extracellular domain with a GPI anchor,
a construct equivalent to one we have used before to identify gB-
specific mAbs [27]. A third vaccinia virus, expressing the N-
terminal third of gp150 with a GPI anchor, has been described
[21]. Infecting MHV-68 carrier mice with each vaccinia
recombinant boosted antibody against the cognate MHV-68
glycoprotein, as evident by flow cytometric staining of glycopro-
tein-transfected cells with immune sera (Fig. 3B).
This boosting correlated with a marked change in the impact of
immune sera on MHV-68 infectivity: VAC-150 increased
RAW264.7 cell infection, consistent with gp150 driving this
process [21], but boosting with VAC-gB or VACgHL reduced it
(Fig. 4A). Boosting with VAC-gB or VAC-gHL also improved the
serum-mediated neutralization of BHK-21 cell infection (Fig. 4B).
Five months after boosting, the neutralization titres of sera pooled
from VAC-gB-boosted or VAC-gHL-boosted mice had declined
somewhat, but they still remained significantly above those of
control mice for both fibroblast (Fig. 5A) and RAW264.7 cell
(Fig. 5B) infections.
gB-specific neutralizing mAbs are only detectable in a minority
of MHV-68-infected mice, possibly because significant neutrali-
zation requires IgM isotype antibodies [28] and most MHV-68-
specific B cells produce IgG [29,30]. We therefore also tested
individual sera for neutralization (Fig. 5C). The titers of VAC-gB-
boosted mice were highly variable. One serum neutralized
strongly-and probably dominated the pooled sample-but others
overlapped with the controls. In contrast, sera from VAC-gHL-
boosted mice all neutralized MHV-68 better than the controls.
This was consistent with gH/gL-specific neutralizing mAbs being
more reliably recovered from MHV-68 carriers [22]. Thus, gHL
was a more uniformly effective post-exposure vaccine for boosting
neutralizing antibodies.
In vivo neutralization
Extrapolating in vitro neutralization to an in vivo setting is not
straightforward. Herpesvirus entry routes into naive hosts are not
well characterized and are probably multiple. We have seen
already with IgG Fc receptors that accessory uptake pathways can
bypass apparent blocks to infection [17]. Lectin-mediated uptake
may do the same [31]. An in vivo test of neutralization is therefore
desirable to confirm that in vitro assays are realistic. One approach
to has been to inject mice with congenic [32] or xenogenic [33]
immune sera. However, MHV-68 infection is simply too
complicated to interpret the effects of such treatments as
neutralization without more direct evidence (see Introduction).
Indeed, it is unlikely that neutralizing antibodies stop cell/cell viral
spread. The major opportunity for neutralizing antibodies to act
comes when cell-free virions pass from an infected to a naive host.
Therefore one major area of complexity to encompass in
neutralization assays is the uptake of antibody-exposed virions at
a mucosal surface. With this in mind, we tested the infectivity of
virions that had been exposed to immune sera by inoculating them
Figure 2. gH/gL-specific antibodies inhibit RAW264.7 macrophage infection by virions exposed to immune serum. Wild-type or gL-deficient (gL
2)
eGFP-expressing virions were incubated with dilutions of immune sera (2 h, 37uC), pooled from 3 mice infected 3 months before with wild-type or
gL-deficient MHV-68. The virus/antibody mixtures were then added to RAW264.7 macrophages (3 p.f.u./cell) or BHK-21 fibroblasts (0.3 p.f.u./cell).1 8h
later, LPS (350 ng/ml) was added for 6 h to maximize viral eGFP expression [17] and infection was quantitated by flow cytometry of eGFP
+ cells. Each
value is expressed as a percentage of the eGFP expression with virus alone. A log scale is used to encompass the huge range between infection
enhancement and neutralization. Virus alone would be 100%, or log=2 (dashed line). The data are from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000899.g002
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PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e899Figure 3. Boosting MHV-68 carrier mice with MHV-68 glycoproteins alters the composition of immune sera. A. Vero cells were left infected (UI) or
infected (1 p.f.u./cell, 18 h) with vaccinia virus recombinants as indicated, then fixed, permeabilized and stained for MHV-68 glycoproteins. T2C12 and
T7G7 see different gH/gL neutralizing epitopes [22]. The data are from 2 separate experiments. B. MHV-68 carrier mice (3 months post-infection) were
infected with vaccinia virus recombinants as shown. The control recombinant (VAC-cont) expresses the murine invariant chain with an ovalbumin-
derived epitope. Sera were taken 10 days post-infection, pooled from 5 mice per group, and used to stain MHV-68 glycoprotein-expressing CHO cell
lines as indicated. nil=untransfected, gHL=transfected with gH/gL-GPI fusion protein, gB=transfected with gB-GPI, gp150=transfected with gp150.
Naive=serum from naive mice. The arrows indicate strong increases in glycoprotein staining. The data are from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000899.g003
Figure 4. Altered functional impact of sera from MHV-68 carrier mice boosted with individual virion glycoproteins. EGFP-expressing MHV-68
virions were incubated with sera from MHV-68 carrier mice boosted 10 days earlier with vaccinia virus recombinant as shown. The virus/antibody
mixtures were then used to infect RAW264.7 macrophages (5 p.f.u./cell) or BHK-21 fibroblasts (100 p.f.u./well). RAW264.7 cell infection was
quantitated 18 h later by flow cytometry of viral eGFP expression. BHK-21 cell infection was measured by plaque assay. The dashed lines show
infection with virus alone (no serum). The data are from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000899.g004
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infection or not, based on virus titers in lung homogenates at
7 days post-inoculation.
In the absence of immune serum, in vivo infectivity was
comparable to in vitro: 1 p.f.u. infected 4/6 mice, consistent with
a Poisson distribution. Serum-mediated neutralization was much
more effective in vitro than in vivo. Thus, 10% immune serum
reduced in vitro infectivity at least 1000-fold (1000 p.f.u. was
reduced to 0 p.f.u.), but reduced in vivo infectivity no more than
100-fold (100 p.f.u. mixed with immune serum still infected 10/14
mice). We then tested in vivo neutralization by the boosted sera
(Fig. 6B). All MHV-68-immune sera neutralized 10 p.f.u. for
intranasal infection, but only the gHL-boosted and gB-boosted
sera completely neutralized 100 p.f.u. and only the gHL-boosted
sera were able to stop at all (3/6 mice) infection by 1000 p.f.u.. In
vivo neutralization was therefore improved significantly by post-
exposure vaccination.
DISCUSSION
Immune sera block MHV-68 infection of fibroblasts, but fail to
block and even enhance its infection of FcR
+ cells such as
macrophages and dendritic cells. At mucosal surfaces, FcR
+ and
DC-SIGN
+ [31] dendritic cell processes [34]; mucosal epithelial
FcRn [35]; and M cell transcytosis [36] all provide potential
uptake routes for antibody-coated virions. Merely blocking cell
binding may therefore not suffice to block viral transmission. In
contrast, membrane fusion is essential for enveloped virions to
infect regardless of the uptake route. It should therefore be
a universally effective neutralization target. gH/gL-specific anti-
bodies block MHV-68 infection at a point between cell binding
Figure 5. Maintenance of altered neutralization responses after boosting of virus carriers. A. Pooled serum samples (5 mice per group) at
5 months post-boosting of MHV-68 carrier mice with the vaccinia virus recombinant shown, were used to inhibit MHV-68 infection of BHK-21 cells in
a plaque reduction assay. The data are from 1 of 3 equivalent experiments. The dashed line shows the titer of the same amount of virus without
added antibody. B. The same serum samples as in A were tested for their effect on RAW264.7 cell infection. eGFP-expressing MHV-68 virions were
incubated with serum dilutions as shown (2 h, 37uC) then added to RAW264.7 macrophages (3 p.f.u./cell). Infection was assayed 18 h later by flow
cytometry of viral eGFP expression. The dashed lines show infection levels for MHV-68 incubated with either no serum or with sera pooled from age-
matched naive mice. The data are from 1 of 2 equivalent experiments. C. Sera from individual vaccinia-boosted, MHV-68 carrier mice, again at
5 months post-boosting, were incubated with MHV-68 virions (2 h, 37uC). The infectivity titer of each serum/virus mixture was then determined by
plaque assay on BHK-21 fibroblasts. Each solid line shows the result for a serum sample from one mouse. The dashed line shows the mean titer of the
group. The dotted line shows the mean titer of 3 virus samples without added immune serum. The data are from 1 of 2 equivalent experiments.
doi:10.1371/journal.pone.0000899.g005
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the infection of both FcR
2 and FcR
+ cells, and can therefore
potentially block all routes into the naive host.
MHV-68 infection elicits gH/gL-specific antibodies, but
quantitative analysis of the glycoprotein-specific antibody reponse
indicates that gH/gL is quite poorly immunogenic [21]. gH/gL
neutralizing epitopes are lost if gL and gH dissociate [22], and B
cells specific for other, more immunogenic virion glycoproteins
probably reduce the gH/gL antigen load [21]. The effectiveness of
gH/gL mAbs and polyclonal sera in blocking MHV-68 infection
argued that poor gH/gL immunogenicity is a crucial factor in
allowing antibody-exposed virions to remain infectious in vivo.W e
showed that the steady state antibody response of virus carriers is
not fixed, but can be modified by post-exposure vaccination.
Subunit vaccination avoided the problem with whole MHV-68 of
eliciting antibodies mainly to gp150, which promote FcR-
dependent infection [21]. By selectively boosting gH/gL-specific
antibody, the balance of immune serum was tipped from
promoting FcR-dependent infection to inhibiting it. In vivo
neutralization-which was notably more difficult for immune sera
to achieve than in vitro neutralization-was also improved.
Immunization with a gH-gL fusion protein therefore has the
potential to improve unfavourable antibody responses in herpes-
virus carriers, and thereby to reduce their infectivity.
The limitation of this approach is likely to be that herpes virions
are intrinsically hard to neutralize. The relatively low efficiency
with which gH/gL-specific mAbs neutralize MHV-68 [22] implies
that the fusion machinery is quite well protected. Even saturating
levels of a MHV-68 gH/gL-specific neutralizing mAb fail to
protect against in vivo infection with 10 p.f.u. MHV-68 (P.G.
Stevenson, unpublished data). Fortunately, polyclonal immune
sera generally neutralize more effectively than monoclonal
antibodies because different antibody specificities can have
synergistic inhibitory effects. It evidently remained feasible for
a boosted, polyclonal gH/gL-specific response to block infection in
vivo. As 1 virion in principle infects no less well than 1000, the
neutralization of 100 p.f.u. by gHL-boosted sera implied that the
average infectivity of each virion could be reduced to less than 1%
of normal for all infection routes. Even if in vivo infectivity is not
abolished completely, the limited transmissibility of persistent
viruses suggests that modest infectivity reductions might suffice to
reduce significantly viral prevalence.
One complication of post-exposure vaccination is that several
herpesviruses assemble alternative fusion complexes [37–39]. The
best vaccine would presumably be the predominant fusion
complex on shed virions-with EBV that incorporating gp42 [40].
It may prove sufficient to target just the fusion complex associated
with the major route into naive hosts, or it may prove necessary to
target more than one fusion complex. Another key task is to test
post-exposure vaccination in an in vivo transmission model. One
has not yet been established for MHV-68. Nevertheless, our study
of MHV-68 shows that while the difficulty of in vivo neutralization
should not be under-estimated, it can in principle be achieved by
boosting antibodies against appropriate virion glycoproteins.
MATERIALS AND METHODS
Mice
BALB/c mice were purchased from Harlan U.K. Ltd. (Bicester,
U.K.), housed in the Cambridge University Department of
Pathology (Home Office Project Licence 80/1992). For immuni-
zation studies, mice were and infected intranasally with 3610
4
PFU MHV-68 when 6–8 weeks old. Vaccinia viruses were given
by intraperitoneal injection (3610
6 PFU). For infection studies,
mice were infected intranasally with virus/antibody mixtures and
lungs were removed for plaque assay 7 days later.
Cells
BHK-21 cells, RAW264.7 cells, CHO and CHO-gB cells [27]
cells, L929-gp150 cells [21], NIH-3T3-CRE cells [41] and
TK
-143 cells were grown in Dulbecco’s modified Eagle medium
(Invitrogen, Paisley, U.K.) supplemented with 2 mM glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal calf
serum (PAA laboratories, Linz, Austria). Where indicated, cells
Figure 6. Neutralization of MHV-68 virions for in vivo infection. A.
Wild-type MHV-68 virions were filtered to remove any aggregates, then
diluted as shown (nominal PFU) and incubated or not with 10% serum
pooled from mice infected 3 months previously with wild-type MHV-68.
Each sample was then titrated on BHK-21 cells (p.f.u.) and used to infect
naive mice intranasally (mice infected). Infection of mice was de-
termined by plaque assay of lungs harvested 7 days later, and were
scored simply as positive or negative depending on whether any virus
was present. The in vivo data are pooled from 3 different experiments
that all gave consistent results. B. Wild-type MHV-68 virions were
incubated with pooled serum samples from vaccinia virus boosted
MHV-68 carrier mice as in A, then given intranasally to naive mice (5 ml
of serum per mouse with the virus dose shown, using 6 mice per
group). Lungs were titered for infectious virus at 7 days post-infection
and scored as either infected or not. The data are pooled from 2
equivalent experiments (3 mice per group each).
doi:10.1371/journal.pone.0000899.g006
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U.K.).
Viruses
MHV-68 was derived from a genomic BAC, which also
transcribes eGFP from a human cytomegalovirus IE-1 promoter
[42]. gL-deficient [26] and gp150-deficient [24] derivatives have
been described. For all in vivo infections, the loxP flanked eGFP
and BAC sequences were removed by passaging viruses through
NIH-3T3-CRE cells. Viruses were grown in BHK-21 cells.
Infected cultures were cleared of infected cell debris by low-speed
centrifugation (10006g, 3 min). Virions were then concentrated
by high speed centrifugation (380006g, 90 min). Virus stocks for
in vivo neutralization assays were also filtered (0.45 mm) to remove
any aggregates. Virus titers of stocks, antibody-treated samples and
lung homogenates were determined by plaque assay on BHK-21
cells [15]. To make gHL-GPI, the gL coding sequence lacking its
stop codon and the first 13 amino acid residues of its signal peptide
[22] was amplified by PCR (Phusion DNA polymerase, New
England Biolabs, Hitchin, U.K.) with NotI-restricted primers and
cloned into the NotI site between gH and its GPI anchor in
pBRAD-gH [22] to make pBRAD-gHL. Residues AFVSLSTC of
the predicted gL signal peptide were retained as a linker between
gL and gH. CHO cells were transfected with pBRAD-gHL to
make CHO-gHL cells. The correct expression of virion gH/gL
epitopes by this cell line was confirmed with.30 gH/gL-specific
mAbs (data not shown). To make VAC-gHL, the gHL-GPI coding
sequence was amplified from pBRAD-gHL using 59 AvrII-
restricted and 39 HinDIII-restricted primers and cloned into the
NheI/HinDIII sites of pMJ601 [43]. To make VAC-gB, the gB-
GPI coding sequence was amplified from pBRAD-gB [27], again
with 59 AvrII-restricted and 39 HinDIII-restricted primers, and
cloned into pMJ601 as for VAC-gHL. pMJ-601-gHL-GPI and
pMJ601-gB-GPI were each transfected into vaccinia virus WR-
infected TK
-143 cells. Thymidine kinase-deficient recombinants
were selected by passage in 25 mg/ml 59-bromo-29-deoxyuridine
(Sigma Chemical Co, Poole, U.K.) and identified by beta
galactosidase expression using X-gal substrate. They were purified
to homogeneity by limiting dilution cloning. VAC-gp150 has been
described [21].
Flow cytometry
Cells infected with eGFP-expressing viruses were washed in PBS
and analysed directly for green channel fluorescence. For specific
staining, cells were incubated with MHV-68 glycoprotein-specific
mAbs (1 h, 4uC), washed62 in PBS, incubated with fluorescein-
conjugated rabbit anti-mouse IgG pAb (Dako Cytomation, Ely,
U.K.), washed62, and analysed on a FACS Calibur (Becton-
Dickinson, Oxford, U.K.). We used the following mAbs. gH/gL:
7D6, 7E5, T4C5, T7G7, T2C12 (all IgG2a), gp150: T1A1, T4G2
(both IgG2a), gB: MG-15B7 (IgG1), gp70: 6H10 (IgG2a).
Immunofluorescence
eGFP expression in live cells was visualised directly. For staining
with MHV-68-specific mAbs, cells were fixed (4% paraformalde-
hyde, 30 min), permeabilized (1% Triton-X100, 15 min), blocked
with 5% fetal calf serum, then incubated with mAbs (1 h),
washed63 in PBS, incubated with Alexa488-conjugated goat anti-
mouse pAb (Invitrogen Corporation, Paisley, U.K.), washed63
and mounted with Prolong Gold antifade (Invitrogen). Fluores-
cence was visualized with an Olympus IX70 microscope plus
a Retiga 2000R camera line (QImaging)
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